



# A randomised controlled study of preoperative oral carbohydrate loading versus fasting in patients undergoing colorectal surgery

Nermina Rizvanović<sup>1</sup> · Višnja Neseć Adam<sup>2,3</sup> · Senada Čaušević<sup>1</sup> · Senad Dervišević<sup>4</sup> · Samir Delibegović<sup>5</sup>

Accepted: 5 July 2019 / Published online: 15 July 2019  
© The Author(s) 2019

## Abstract

**Purpose** This study aimed to evaluate the effect of preoperative carbohydrate oral (CHO) loading on the postoperative metabolic and inflammatory response, perioperative discomfort and surgical clinical outcomes in open colorectal surgery compared with a conventional fasting protocol.

**Methods** Fifty patients were randomly allocated to either the intervention group (CHO), to receive preoperative oral carbohydrate supplementation, or the control group (FAST), to undergo preoperative fasting. Insulin resistance, insulin sensitivity, the Glasgow Prognostic Score (GPS) and IL-6 levels were analysed at 06 h on the day of surgery (T<sub>1</sub>), 6 h after surgery (T<sub>2</sub>) and at 06 h on postoperative day 1 (T<sub>3</sub>) and postoperative day 2 (T<sub>4</sub>). Thirst, hunger, dry mouth, weakness, anxiety and pain were assessed using the visual analogue scale (VAS) prior to anaesthesia induction and at 0–4, 4–8, 8–12 and 12–24 h after surgery. Surgical clinical outcomes included the return of gastrointestinal function, time to independent ambulation and postoperative discharge day.

**Results** Postoperative insulin resistance was 30% lower ( $p < 0.03$ ) and insulin sensitivity was 15% higher ( $p < 0.05$ ) in the CHO group than in the FAST group. The GPS was lower in the CHO group at T<sub>1</sub> ( $p < 0.001$ ), T<sub>3</sub> ( $p < 0.01$ ) and T<sub>4</sub> ( $p < 0.004$ ). IL-6 serum levels were lower at the analysed postoperative time points in the CHO group ( $p < 0.001$ ). The VAS well-being score was lower in the intervention group ( $p < 0.001$ ); however, the VAS pain score was not significantly different between the groups. The evaluated surgical outcomes appeared earlier in the CHO group ( $p < 0.001$ ).

**Conclusion** A preoperative CHO drink reduced the postoperative metabolic and inflammatory response and improved subjective well-being and surgical clinical outcomes but did not diminish the VAS pain score.

**Keywords** Insulin resistance · Preoperative fasting · Preoperative carbohydrate · Visual analogue scale · Colorectal surgery

✉ Nermina Rizvanović  
rizvanovic.nermina@gmail.com

<sup>1</sup> Department of Anesthesiology and Intensive Care Unit, Cantonal Hospital Zenica, 67 Crkvice St, 72 000 Zenica, Bosnia and Herzegovina

<sup>2</sup> University Department of Anesthesiology, Resuscitation and Intensive Care, Clinical Hospital Sveti Duh, 64 Sveti Duh St, 10 000 Zagreb, Croatia

<sup>3</sup> Faculty of Medicine, J.J. Strossmayer Osijek, Osijek, Croatia

<sup>4</sup> Department of Surgery, Cantonal Hospital Zenica, 67 Crkvice St, 72 000 Zenica, Bosnia and Herzegovina

<sup>5</sup> Department of Surgery, University Clinical Center Tuzla, Trnovac St, 75 000 Tuzla, Bosnia and Herzegovina

## Introduction

Preoperative fasting increases perioperative insulin resistance (PIR) and patient discomfort. Surgery itself, especially a major procedure such as colorectal surgery, induces an endocrine and inflammatory stress response and contributes to PIR [1].

PIR has a central role in the metabolic response to surgical injury. Contra-regulating hormones diminish peripheral insulin activity. PIR is a state of reduced insulin-mediated glucose uptake in skeletal muscles and adipose tissue, with an increased glucose release due to hepatic gluconeogenesis and hyperglycaemia. A catabolic state occurs with the depleted storage of glycogen via glycogenolysis, muscle protein loss and lipolysis [2]. The purpose of PIR is to provide energy and glycaemic substrates to glucose-dependent tissues. PIR is an adaptive mechanism, but it can be harmful if left untreated,

increasing postoperative morbidity and mortality and prolonging the hospital stay [3].

Strategies to reduce the postoperative stress response and PIR include shortening the preoperative fasting time via preoperative carbohydrate oral (CHO) drink administration. Preoperative fasting is the first step in PIR development [4]. The traditional fasting time of 6–8 h before elective surgery to prevent pulmonary aspiration usually extends up to 12 h in anaesthetic practise. Overnight fasting is a physiological state of reduced insulin sensitivity due to the normal hormonal diurnal rhythm. If patients undergo surgery in the prolonged fasted state, insulin resistance may begin even before surgery. A preoperative CHO drink acts as a morning meal, improves insulin sensitivity and propels the patient's metabolic state towards anabolism [5]. The effectiveness of CHO loading for the occurrence of PIR has been assessed by many investigators, but various methodological approaches and study protocols have resulted in contradictory findings between studies [6–8].

Preoperative fasting and surgical tissue damage activate inflammatory pathways mediated by various cytokines [9]. Increasing the level of interleukin 6 (IL-6), reduces insulin action and contributes to PIR. IL-6 stimulates the acute phase of protein synthesis, such as C-reactive protein (CRP), and inhibits the synthesis of albumin [10]. An increased CRP level after colorectal surgery is a reliable marker of the systemic inflammatory response (SIRS) [11]. A decreasing level of postoperative albumin is correlated with previous malnutrition and the severity of illness [12]. The ratio of inflammatory to nutritional factors, CRP/albumin, is known as the Glasgow Prognostic Score (GPS), which is a useful tool for predicting infectious complications, morbidity and mortality after colorectal surgery [13].

The present study evaluated the overall effectiveness of a preoperative CHO drink in terms of the postoperative metabolic and inflammatory response, perioperative discomfort and surgical clinical outcomes in open colorectal surgery as a model of major surgery.

The aim of this study was to compare the differences between preoperative CHO loading and a conventional fasting protocol on the PIR, GPS score, IL-6 level, subjective patient well-being, visual analogue scale (VAS) pain score and surgical clinical outcomes.

## Methods


### Patients and study design

This prospective, randomised controlled clinical study was carried out in the Department of Anesthesiology, Intensive Care Unit and Department of Surgery at Cantonal Hospital in Zenica, Bosnia and Herzegovina. After obtaining ethical

committee approval and written patient consent, 50 patients with an American Society of Anesthesiologist (ASA) physical status of I-II, between 18 and 70 years of age and scheduled for elective open colorectal surgery were included in this study. The study was registered in [ClinicalTrials.gov](https://clinicaltrials.gov) (number NCT03793036).

Patients with previous treatment for colorectal cancer, disseminated malignant disease, an increased risk of gastric content aspiration, body mass index below 20 or above 30 kg/m<sup>2</sup> or an overall score  $\geq 3$  according to the Nutritional Risk Screening 2002 (NRS-2002) were excluded from the study [14]. Additional exclusion criteria were emergency colorectal surgery, diabetes mellitus, inflammatory bowel disease, immunomodulatory therapy, a history of allergy to any study drug and the patient's refusal to participate in the study. The day before surgery, patients who fulfilled the study criteria were randomly allocated into two groups of 25 patients. Randomisation was performed using computer-generated random numbers indicating the treatment, which were held in sealed opaque envelopes. The researcher who conducted the randomisation and opened the envelopes the night before surgery was blinded by the study protocol, as were the staff involved in the medical procedures and data collection process. The progress of the patients throughout the randomised trial is shown in Fig. 1.

Patients in the FAST group (control group) fasted for 8 h before surgery. Patients in the CHO group (intervention group) received 400 mL of a clear carbohydrate drink (12.5 g/100 mL maltodextrin, 50 kcal/100 mL, pH 5.0) at 22 h on the evening before surgery and another 200 mL of the carbohydrate drink on the day of surgery, 2 h before anaesthesia induction. The night before surgery, diazepam 5 mg (intramuscular) and low-molecular-weight heparin (subcutaneous) were administered to all patients. Preoperatively, there was no intravenous administration of the fluids. Open radical resection of colorectal cancer was performed in all patients under general endotracheal anaesthesia. Sixty minutes before surgery, a prophylactic dose of the first generation of cephalosporin was administered intravenously. Three minutes before anaesthesia induction, all patients received midazolam 0.05 mg/kg intravenously and were preoxygenated with 100% oxygen by facial mask. Anaesthesia was induced with propofol 3 mg/kg, fentanyl 3  $\mu$ g/kg and pancuronium-bromide 0.1 mg/kg. Balanced anaesthesia was maintained using sevoflurane minimum alveolar concentration 0.5–1% and N<sub>2</sub>O 50% in oxygen, at a total flow of 2 L/min and with intermittent bolus doses of fentanyl and pancuronium. Intraoperative fluid management was limited to a glucose-free solution and no exogenous insulin administration. At the end of surgery, the neuromuscular block was reversed with neostigmine 0.05 mg/kg and atropine 0.02 mg/kg. The patients were extubated when fully awake. Postoperative care was standardised as clinically indicated and

**Fig. 1** CONSORT flow diagram of the study design

a free fluid regimen was permitted. Early postoperative mobilisation was recommended.

### Data collection and definitions

*Clinical biochemical parameters* were assessed from peripheral venous blood samples, taken at 06 h on the day of surgery ( $T_1$ , basal value), 6 h after surgery ( $T_2$ ), at 06 h on postoperative day 1 ( $T_3$ ) and at 06 h on postoperative day 2 ( $T_4$ ). Serum levels of glucose, insulin, CRP, albumin and IL-6 were evaluated. Postoperatively, patients did not receive intravenous glucose or oral nutrition 6 h prior to the morning testing, from midnight to 06 h. Serum glucose was measured using the hexokinase/glucose-6-phosphate dehydrogenase enzymatic method, for which the range of normality (r.n.) is 3.3–6.1 mmol/L. Serum insulin (r.n. 3–17  $\mu\text{U}/\text{mL}$ ) was determined by a solid-phase, two-site chemiluminescent immunometric assay. Insulin resistance was calculated using the homeostasis model assessment of insulin resistance (HOMA-IR), according to the following equation:  $\text{HOMA-IR} = [\text{fasting insulin } (\mu\text{U}/\text{mL}) \times \text{fasting glucose } (\text{mmol}/\text{L})] / 22.5$ .  $\text{HOMA-IR} > 1$  indicated the presence of insulin resistance. Insulin sensitivity (r.n. 100%) was calculated using the following equation:  $\text{HOMA-ISI} (\text{insulin sensitivity index}) = 1 / \log[\text{fasting glucose } (\text{mmol}/\text{L}) + \text{fasting insulin } (\mu\text{U}/\text{mL})]$ . HOMA-IR and ISI were processed with a computer model HOMA 2 Calculator version 2.2. Serum CRP (r.n. 0–5 mg/L) was monitored using an automatic immunonephelometry technique. Serum albumin (r.n. 35–48 g/L) was analysed

using the bromocresol green colorimetric method. The GPS was calculated as follows: an elevated level of CRP  $> 10 \text{ mg}/\text{L}$  and hypoalbuminemia  $< 35 \text{ g}/\text{L}$  were allocated a score of 2, and one or neither of these biochemical abnormalities was assigned a score of 1 or 0, respectively. The serum IL-6 concentration (r.n. 0–5.9 pg/mL) was measured using enzyme-linked immunosorbent assay test kits.

*Subjective patient well-being and pain scores* were assessed prior to anaesthesia induction and were repeated at 0–4, 4–8, 8–12 and 12–24 h after surgery. Thirst, hunger, mouth dryness, anxiety, weakness, pain at rest and pain with mobilisation scores were measured using a 10-cm horizontal VAS scale. The patients were instructed on how to use the VAS scale. The scales were limited by a vertical line at the left end that represented ‘no symptom’ (score of 0) and a vertical line at the right end that represented ‘the worst imaginable symptom’ (score of 10). The patients marked somewhere on the VAS line. The distance from 0 to the patient’s mark on the VAS line determined the score of the perceived symptom. The combination of metamizole sodium 1.25 g and tramadol hydrochloride 100 mg was administered intravenously for a VAS score  $> 3$  or if the patient reported pain. If analgesia was not achieved or the VAS score was  $> 5$ , an additional dose of tramadol hydrochloride 25 mg was provided. The time to the first postoperative analgesic dose and the number of additional analgesic doses were noted.

Nausea was defined as an unpleasant sensation referring to a desire to vomit without expulsive muscular movement. Vomiting was defined as the forceful expulsion of even a

small amount of gastrointestinal contents through the mouth. The patients were questioned about the presence of nausea and vomiting at five study time points. The answer ‘no’ was graded as 1, and the answer ‘yes’ was graded as 2. The presence of nausea during 30 min, more than one episode of vomiting during 15 min or the patient’s request for antiemetic drugs was treated with thiethylperazine 10 mg intravenously. The number of antiemetic drug doses was recorded.

*Surgical outcomes* were evaluated by the postoperative return of gastrointestinal function, time to independent ambulation and postoperative discharge day. The sounds of the bowel were analysed by an abdominal auscultation at 24, 36, 48, 60, 72 and 80 h, postoperatively. The time of the first postoperative flatus and the time of the first postoperative defecation were recorded. In addition, gender, age, body weight, body mass index, NRS-2002 score, ASA physical status class, type of surgery, operation time and intraoperative blood loss were collected.

## Statistical analysis

The data analysis was performed using the Statistical Package for the Social Sciences (SPSS v23.0; IBM Corp., Armonk, NY, USA). The sample size was estimated using sample size calculator software and a power analysis with a 95% confidence interval and power of 80%. Statistical significance was considered  $p < 0.05$ . The calculation indicated that 19 patients

per group would be sufficient to detect a 50% difference for insulin resistance between the groups. Assuming dropout led to a total sample size of 50 patients. Categorical variables were analysed using Pearson’s chi-squared test and presented as the frequency and relative number of cases (percentage). Parametric variables were expressed as the mean and standard deviation or median and range as appropriate. For comparisons, Student’s *t* test, a one-way analysis of variance (ANOVA) or the Mann-Whitney *U* test was used, depending on the type and distribution of the data.

## Results

All 50 of the recruited participants completed the study and were included in the analysis. There were no statistically significant differences in the demographic or surgical data between the groups, which is summarised in Table 1.

## Clinical biochemical parameters

*Insulin resistance parameters*, i.e., serum glucose, insulin and HOMA-IR levels, were higher in the FAST group than in the CHO group during all study periods. HOMA-ISI levels were lower in the FAST group than in the CHO group. Statistical significance of the differences between groups is presented in Table 2.

**Table 1** Demographic characteristics of the groups

Group parameters	FAST group ( $n = 25$ )	CHO group ( $n = 25$ )	<i>p</i>
Gender, male/female, <i>n</i> (%)	13/12 (52/48)	14/11 (56/44)	0.777
Age (years) mean $\pm$ SD	60.2 $\pm$ 9.7	61.0 $\pm$ 7.3	0.758
Body weight (kg) mean $\pm$ SD	79.3 $\pm$ 12	81.2 $\pm$ 10.0	0.313
Body mass index (kg/m <sup>2</sup> ) mean $\pm$ SD	24.7 $\pm$ 1.6	26.4 $\pm$ 4.5	0.116
NRS-2002 score I/II, <i>n</i> (%)	15/10 (60/40)	13/12 (52/48)	0.569
ASA I/II, <i>n</i> (%)	7/18 (28/72)	8/17 (32/68)	0.785
Type of surgery, <i>n</i> (%)			
Hemicolectomia right	8 (32)	9 (36)	
Operation Dixon	9 (36)	7 (28)	
Operation Hartman	3 (12)	4 (16)	
Operation Miles	5 (20)	4 (16)	0.860
Proctocolectomia	0 (0)	1 (4)	
Operation time (min) mean $\pm$ SD	137.6 $\pm$ 28.9	143.2 $\pm$ 39.4	0.570
Blood loss, <i>n</i> (%)			
< 300 ml	21 (84)	20 (80)	0.713
> 300 ml	4 (16)	5 (20)	

Student’s *t* test and  $\chi^2$  test were used for the analysis, and  $p < 0.05$  was considered statistically significant. *SD*, standard deviation; *FAST group*, preoperative fasting group; *CHO group*, preoperative carbohydrate loading group; *NRS-2002*, Nutrition Risk Score-2002; *ASA*, American Society of Anesthesiologists

**Table 2** Mean values of insulin resistance parameters according to the groups and study time points

Parameter	Time	FAST group ( <i>n</i> = 25)		CHO group ( <i>n</i> = 25)		<i>p</i>
		Mean ± SD	95%CI	Mean ± SD	95%CI	
Glucose (mmol/L)	T <sub>1</sub>	6.5 ± 1.1	1.0–2.0	5.0 ± 0.6	1.0–2.0	0.001
	T <sub>2</sub>	7.5 ± 1.5	0.9–2.4	5.8 ± 1.1	0.9–2.4	0.001
	T <sub>3</sub>	7.3 ± 1.6	–0.1–1.6	6.6 ± 1.4	0.1–1.6	0.102
	T <sub>4</sub>	6.7 ± 1.1	0.2–1.5	5.8 ± 0.9	0.2–1.5	0.005
Insulin (μU/mL)	T <sub>1</sub>	5.4 ± 0.7	1.0–1.9	3.8 ± 0.8	1.0–1.9	0.001
	T <sub>2</sub>	9.8 ± 1.6	3.0–4.4	6.0 ± 0.5	3.0–4.4	0.001
	T <sub>3</sub>	17.6 ± 4.1	6.6–10.0	9.3 ± 1.1	6.6–10.1	0.001
	T <sub>4</sub>	13.1 ± 1.6	5.3–6.8	7.0 ± 0.9	5.3–6.8	0.001
HOMA-IR	T <sub>1</sub>	0.7 ± 0.1	0.2–0.3	0.4 ± 0.0	0.2–0.3	0.001
	T <sub>2</sub>	1.4 ± 0.2	0.4–0.6	0.8 ± 0.0	0.4–0.6	0.001
	T <sub>3</sub>	2.4 ± 0.5	0.9–1.4	1.2 ± 0.1	0.9–1.4	0.001
	T <sub>4</sub>	1.7 ± 0.1	0.7–0.8	0.9 ± 0.1	0.7–0.8	0.001
HOMA-ISI	T <sub>1</sub>	136.8 ± 21.3	83.4–54.5	205.8 ± 28.8	83.4–54.5	0.001
	T <sub>2</sub>	74.8 ± 12.9	54.6–41.0	122.7 ± 10.8	54.6–41.0	0.001
	T <sub>3</sub>	43.1 ± 10.8	43.5–31.3	80.6 ± 10.6	43.5–31.3	0.001
	T <sub>4</sub>	56.8 ± 5.8	56.1–43.8	106.8 ± 14.1	56.2–43.7	0.001

Student's *t* test was used for the analysis, and *p* < 0.05 was considered statistically significant

SD, standard deviation; CI, confidence interval; FAST group, preoperative fasting group; CHO group, preoperative carbohydrate loading group; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-ISI, homeostasis model assessment of insulin sensitivity index; T<sub>1</sub>, 06 h on the day of surgery; T<sub>2</sub>, 6 h after surgery; T<sub>3</sub>, 06 h on postoperative day 1; T<sub>4</sub>, 06 h on postoperative day 2

The mean value of HOMA-IR in the FAST group increased by 85% 6 h after surgery and 76% on postoperative day 1, while there was a 27% decrease on postoperative day 2. In the CHO group, the mean value of HOMA-IR increased by 74% 6 h after surgery and 55% on postoperative day 1, while there was a 25% decrease on postoperative day 2. The total increase in HOMA-IR was 30% lower in the CHO group than in the FAST group (*p* < 0.03).

HOMA-ISI had a 44% decline at 6 h after surgery and a 41% decline on postoperative day 1 in the FAST group, followed by a 31% increase on postoperative day 2. In the CHO group, HOMA-ISI decreased by 39% 6 h after surgery and 32% on postoperative day 1, while it increased by 32% on postoperative day 2. The total reduction in HOMA-ISI was 54% in the FAST group versus 39% in the CHO group (*p* < 0.05).

Inflammatory response parameters were elevated after surgery in both groups, except for serum albumin, which decreased. Significantly greater CRP levels were seen in the FAST group, with the peak on postoperative day 2 in both groups. Serum albumin decreased significantly between each studied time point in the FAST group (*p* < 0.05) but did not decrease significantly in the CHO group. Higher GPS scores were found in the FAST group, with a maximum grade of 2 in 25 (100%) patients versus 17 (68%) patients in the CHO group on postoperative day 2 (*p* < 0.004). Significantly higher

levels of IL-6 were displayed in the FAST group. The peak was recorded 6 h postoperatively and further declined, but there was no return to the baseline in any group (Table 3).

### Subjective patient well-being parameters and VAS pain score

The VAS scores of the subjective well-being parameters were significantly higher in patients who fasted than in those who CHO loaded preoperatively. The incidence of nausea and the number of antiemetic requests was significantly higher in the FAST group (*p* < 0.02 and *p* < 0.04, respectively). The incidence of vomiting was not significantly different between the groups (Table 4).

There were no statistically significant differences in the VAS pain score or the number of additional analgesic doses between the study groups. The time to first postoperative analgesic dose was shorter in the FAST group (Table 5).

### Surgical clinical outcomes

Participants in the CHO group had a significantly faster return of gastrointestinal function; intestinal sounds were heard earlier, and the times to first flatus, first defecation and oral intake were shorter. Independent ambulation and postoperative discharge day occurred earlier in the CHO group (Table 6).

**Table 3** Mean values of inflammatory response parameters according to the groups and study time points

Parameter	Time	FAST group ( <i>n</i> = 25)		CHO group ( <i>n</i> = 25)		<i>p</i>
		Mean ± SD	95%CI	Mean ± SD	95%CI	
CRP (mg/L)	T <sub>1</sub>	14.9 ± 3.7	7.6–11.1	5.5 ± 2.2	7.6–11.1	0.001
	T <sub>2</sub>	52.7 ± 17.2	27.0–41.8	18.3 ± 5.4	27.0–41.8	0.001
	T <sub>3</sub>	93.8 ± 16.9	22.3–41.8	62.9 ± 12.7	22.3–39.4	0.001
	T <sub>4</sub>	125.3 ± 21.9	31.9–51.0	83.8 ± 9.1	31.8–51.1	0.001
Albumin (g/L)	T <sub>1</sub>	40.4 ± 3.2	–0.8–2.7	39.4 ± 3.0	–0.8–2.7	0.294
	T <sub>2</sub>	34.8 ± 3.1	–3.0–0.4	36.1 ± 2.9	–3.0–0.4	0.133
	T <sub>3</sub>	31.7 ± 2.2	–3.4–0.7	33.8 ± 2.6	3.4–0.7	0.030
	T <sub>4</sub>	28.6 ± 2.1	4.9–2.3	32.2 ± 2.4	–4.9–2.3	0.001
GPS	T <sub>1</sub>	0.9 ± 0.4	0.4–0.9	0.2 ± 0.5	0.4–0.9	0.001
	T <sub>2</sub>	1.4 ± 0.5	–1.8–0.4	1.3 ± 0.4	–1.8–0.4	0.421
	T <sub>3</sub>	1.8 ± 0.3	0.0–0.5	1.5 ± 0.5	0.0–0.5	0.011
	T <sub>4</sub>	2.0 ± 0.0	0.0–0.4	1.7 ± 0.4	0.0–0.4	0.004
IL-6 (pg/mL)	T <sub>1</sub>	5.3 ± 3.0	–0.3–2.5	4.2 ± 1.8	–0.3–36.3	0.123
	T <sub>2</sub>	347.4 ± 155.1	159.6–287.8	123.7 ± 36.3	158.2–289.1	0.001
	T <sub>3</sub>	143.2 ± 41.5	77.2–112.4	48.4 ± 14.0	76.9–112.7	0.001
	T <sub>4</sub>	48.5 ± 17.2	20.8–36.3	19.9 ± 8.6	20.7–36.3	0.001

Student's *t* test was used for the analysis, and *p* < 0.05 was considered statistically significant

SD, standard deviation; CI, confidence interval; FAST group, preoperative fasting group; CHO group, preoperative carbohydrate loading group; CRP, C-reactive protein; GPS, Glasgow Prognostic Score; IL-6, interleukin 6; T<sub>1</sub>, 06 h on the day of surgery; T<sub>2</sub>, 6 h after surgery; T<sub>3</sub>, 06 h on postoperative day 1; T<sub>4</sub>, 06 h on postoperative day 2

## Discussion

While previous studies have focused on certain aspects of preoperative CHO loading in patients undergoing colorectal surgery, our study provides a comprehensive assessment of all the aspects considered to be the effects of a CHO drink. This study encompassed biochemical outcomes (metabolic and inflammatory responses), psychological outcomes (patient well-being and pain scores) and functional surgical outcomes (return of gastrointestinal function, time to independent ambulation and postoperative discharge day).

The present study suggested that a CHO drink taken the evening before open colorectal surgery and 2 h before the induction of anaesthesia provided better postoperative glycaemic control, reduced PIR by 30%, enhanced insulin sensitivity by 15% and attenuated the inflammatory response in terms of lower GPS scores and IL-6 levels compared with the traditional concept of preoperative fasting.

Although all participants were normoglycaemic upon admission to the hospital, preoperative fasting diminished insulin activity and peripheral glucose uptake; therefore, in the FAST group, preoperative hyperglycaemia occurred and was maintained after surgery during the study period. This study confirmed the results of Sio et al. that preoperative CHO loading provided lower glycaemia and insulinaemia ranges after colectomy [15]. Maintaining postoperative euglycaemia

reduces the infection rate and multiple organ failure, while glycaemia > 7 mmol/L increases mortality 18-fold [16].

Open colorectal surgery affects the homeostatic balance via extensive surgical stress. Preoperative CHO drink loading is a part of the enhanced recovery after surgery (ERAS) programme, which is applied in colorectal surgery to reduce stress response, PIR and hospital stay [17]. Applying new protocols is not always a simple process. The role of a preoperative CHO drink has remained controversial. A systematic review of 18 randomised clinical trials established a beneficial effect of preoperative CHO fluids on PIR in oncologic surgery [18], although Peixe-Machado et al. did not find such an influence in gastrointestinal oncologic surgery [19]. Inconsistencies were due to heterogeneity of the samples, surgical procedures, anaesthetic protocols, evaluated variables and measurement methods. The presented study controlled many of the PIR risk factors via the inclusion and exclusion criteria to minimise the bias. Each patient underwent a preoperative nutritional status assessment using the NRS-2002 score. A score ≥ 3 identified patients at nutritional risk and those with a metabolic stress response induced by malignant disease, and these patients were excluded from the study to avoid the influence of malnutrition and disease severity on the research results. In our study, preoperative fasting maintained PIR through the observed postoperative period, and the most prominent was on postoperative day 1. In the CHO group, PIR

**Table 4** Comparison of perioperative well-being parameters according to the groups and study time points

Parameter	Time	FAST group ( <i>n</i> = 25)		CHO group ( <i>n</i> = 25)		<i>p</i>
		Mean ± SD	95%CI	Mean ± SD	95%CI	
Thirst	T <sub>1</sub>	20.8 ± 2.2	14.8–18.2	4.2 ± 3.6	4.8–18.2	0.001
	T <sub>2</sub>	33.6 ± 4.6	24.2–28.7	7.1 ± 3.1	24.2–28.8	0.001
	T <sub>3</sub>	41.1 ± 4.5	18.8–23.6	19.8 ± 3.9	18.8–23.6	0.001
	T <sub>4</sub>	49.1 ± 4.7	23.6–28.2	23.1 ± 3.2	23.6–28.3	0.001
	T <sub>5</sub>	58.4 ± 3.6	28.3–32.8	27.8 ± 4.2	28.3–2.8	0.001
Hunger	T <sub>1</sub>	23.8 ± 3.0	20.5–23.8	1.6 ± 2.7	20.5–23.8	0.001
	T <sub>2</sub>	30.5 ± 3.3	23.7–26.7	5.2 ± 1.7	23.7–26.8	0.001
	T <sub>3</sub>	45.1 ± 4.3	27.9–32.3	14.9 ± 3.3	27.9–32.3	0.001
	T <sub>4</sub>	51.1 ± 3.5	29.4–33.3	19.6 ± 3.3	29.4–33.3	0.001
	T <sub>5</sub>	56.8 ± 5.4	30.3–35.9	23.6 ± 4.3	30.3–35.9	0.001
Dry mouth	T <sub>1</sub>	18.0 ± 1.6	14.5–16.7	2.3 ± 2.1	14.5–16.7	0.001
	T <sub>2</sub>	29.3 ± 4.1	22.6–26.2	4.8 ± 1.9	22.5–26.2	0.001
	T <sub>3</sub>	37.7 ± 2.8	28.6–31.3	7.7 ± 2.0	28.5–31.4	0.001
	T <sub>4</sub>	39.7 ± 4.1	25.6–29.3	12.2 ± 2.0	25.5–29.3	0.001
	T <sub>5</sub>	46.5 ± 5.9	24.6–29.6	19.4 ± 2.1	24.5–29.7	0.001
Weakness	T <sub>1</sub>	9.8 ± 3.0	8.6–11.0	0.0 ± 0.0	8.5–11.0	0.001
	T <sub>2</sub>	25.7 ± 3.3	12.5–16.5	11.2 ± 3.6	12.5–16.5	0.001
	T <sub>3</sub>	31.8 ± 3.0	10.2–13.8	19.8 ± 3.1	10.2–13.8	0.001
	T <sub>4</sub>	36.7 ± 3.7	19.3–23.2	15.4 ± 3.1	19.3–23.2	0.001
	T <sub>5</sub>	42.9 ± 4.5	27.4–31.7	13.3 ± 2.7	27.4–31.7	0.001
Anxiety	T <sub>1</sub>	11.6 ± 2.9	9.3–12.1	0.9 ± 1.9	9.3–12.1	0.001
	T <sub>2</sub>	27.6 ± 4.0	16.2–20.5	9.2 ± 3.4	16.2–20.5	0.001
	T <sub>3</sub>	32.3 ± 3.5	19.0–23.6	10.9 ± 4.3	19.0–23.6	0.001
	T <sub>4</sub>	24.8 ± 3.4	18.5–21.9	4.6 ± 2.3	18.5–21.9	0.001
	T <sub>5</sub>	21.6 ± 3.0	20.4–22.8	0.0 ± 0.0	20.3–22.9	0.001
Nausea, <i>n</i> (%)	T <sub>1</sub>	0 (0)		0 (0)		/
	T <sub>2</sub>	7 (28)		1 (4)		0.02
	T <sub>3</sub>	6 (24)		1 (4)		0.04
	T <sub>4</sub>	3 (12)		1 (4)		0.29
	T <sub>5</sub>	0 (0)		0 (0)		/
Vomiting, <i>n</i> (%)	T <sub>1</sub>	0 (0)		0 (0)		/
	T <sub>2</sub>	3 (12)		1 (4)		0.29
	T <sub>3</sub>	0 (0)		0 (0)		/
	T <sub>4</sub>	1 (4)		1 (4)		1.00
	T <sub>5</sub>	0 (0)		0 (0)		/
Antiemetic drug dose, <i>n</i> (%)		6 (24)		1 (4)		0.04

Student's *t* test and  $\chi^2$  test were used for the analysis, and  $p < 0.05$  was considered statistically significant. *SD*, standard deviation; *CI*, confidence interval; *FAST group*, preoperative fasting group; *CHO group*, preoperative carbohydrate loading group; *T<sub>1</sub>*, prior anaesthesia induction; *T<sub>2</sub>*, 0–4 h after surgery; *T<sub>3</sub>*, 4–8 h after surgery; *T<sub>4</sub>*, 8–12 h after surgery; *T<sub>5</sub>*, 12–24 h after surgery

appeared only on postoperative day 1. Amer et al. confirmed that CHO loading reduced PIR in elective surgery [20]. A lower HOMA-IR index was reported by Vigano et al. in major abdominal surgery with preoperative CHO treatment. Vigano's study recorded higher PIR levels compared with our results because various types of abdominal surgery in that study induced different intensities of surgical stress [21].

Possible mechanisms to reduce PIR via a CHO drink are the activation of glucose transporter 4 on the plasma membrane, improving glycogen synthase activity and the activation of insulin signalling pathways via protein kinase B [22].

In the state of PIR, insulin non-dependent cells such as immunocytes are overloaded with glucose and produce reactive oxygen species that enhance inflammation. Inflammation, in

**Table 5** Mean values of the VAS pain score according to the groups and study time points

Parameters	Time	FAST group ( <i>n</i> = 25)		CHO group ( <i>n</i> = 25)		<i>p</i>
		Mean ± SD	95%CI	Mean ± SD	95%CI	
Pain at rest	T <sub>1</sub>	0.0 ± 0.0	0.0–0.0	0.0 ± 0.0	0.0–0.0	–
	T <sub>2</sub>	3.1 ± 7.9	– 1.8–8.8	32.6 ± 10.6	– 1.8–8.8	0.19
	T <sub>3</sub>	46.2 ± 9.5	– 2.1–8.7	42.9 ± 9.4	– 2.1–8.7	0.22
	T <sub>4</sub>	25.4 ± 5.1	– 2.0–3.7	24.5 ± 4.9	– 2.0–3.7	0.56
	T <sub>5</sub>	6.1 ± 6.3	– 3.0–3.9	5.6 ± 6.0	– 3.0–3.9	0.80
Pain with mobilisation	T <sub>1</sub>	0.0 ± 0.0	0.0–0.0	0.0 ± 0.0	0.0–0.0	–
	T <sub>2</sub>	40.4 ± 8.86	– 4.0–6.6	39.1 ± 9.7	– 4.0–6.6	0.62
	T <sub>3</sub>	50.5 ± 10.5	– 3.2–8.1	48.0 ± 9.1	– 3.1–8.1	0.38
	T <sub>4</sub>	30.4 ± 5.1	– 2.3–3.9	29.6 ± 5.7	– 2.3–3.9	0.60
	T <sub>5</sub>	10.0 ± 7.9	– 3.0–5.5	8.7 ± 6.7	– 3.0–5.5	0.55
Time to first analgesic dose (h)		1.9 ± 1.0	– 2.0–0.3	3.1 ± 1.8	– 2.0–0.3	0.006
Additional analgesic dose, <i>n</i> (%)		9 (36)		6 (24)		0.35

Student's *t* test and  $\chi^2$  test were used for the analysis, and  $p < 0.05$  was considered statistically significant

SD, standard deviation; CI, confidence interval; FAST group, preoperative fasting group; CHO group, preoperative carbohydrate loading group; T<sub>1</sub>, prior anaesthesia induction; T<sub>2</sub>, 0–4 h after surgery; T<sub>3</sub>, 4–8 h after surgery; T<sub>4</sub>, 8–12 h after surgery; T<sub>5</sub>, 12–24 h after surgery

turn, amplifies PIR in a vicious cycle [23]. In the present study, preoperative fasting was correlated with greater acute-phase protein disturbance, a higher GPS and higher IL-6 levels. A preoperative CHO drink significantly attenuated the immune reaction but did not have a strong enough effect to stop it. Researchers have found a lower acute phase response after cholecystectomy [24] and lower IL-6 levels after colorectal resection due to a preoperative CHO drink [25]. A higher GPS score after colorectal surgery predicts cachexia and a poorer survival rate [26]. Increased IL-6 and CRP levels for more than three postoperative days indicate the development of SIRS [27]. By reducing these biomarkers, a preoperative CHO drink could be effective in the preservation of postoperative immunological homeostasis.

The fasting period before surgery alerts patients' mental and physical conditions. Patients become dehydrated,

unable to concentrate and generally unfit. A preoperative CHO drink is recommended to achieve preoperative euvolemia and caloric intake [28]. In this study, a CHO drink strengthened patients' general well-being compared with the FAST group. Lower feelings of thirst, hunger and dry mouth were probably primary effects of the CHO drink related to energy supply and hydration. Reductions in the VAS anxiety and weakness scores were secondary effects. A significant decline from the basal values of the VAS anxiety and hunger scores has been detected after CHO administration in elective surgery [29]. In our study, the VAS anxiety score declined at 8–12 and 12–24 h after surgery, while the weakness score declined at 12–24 h after surgery. Henrixen et al. found no influence on the VAS well-being score after CHO administration in colorectal surgery. The anaesthesia protocol in this study included

**Table 6** Results of the of surgical clinical outcomes according to the groups

Outcomes	FAST group ( <i>n</i> = 25)		CHO group ( <i>n</i> = 25)		<i>p</i>
	Mean ± SD	95%CI	Mean ± SD	95%CI	
Intestinal sounds heard (h)	56.8 ± 11.4	3.6–14.9	47.5 ± 8.1	3.6–14.9	0.002
Time to first flatus (days)	3.1 ± 0.5	0.3–0.8	2.5 ± 0.5	0.3–0.8	0.001
Time to first defecation (days)	4.0 ± 0.9	0.4–1.2	3.2 ± 0.4	0.4–1.2	0.000
Time to oral intake (days)	4.1 ± 0.5	0.2–0.8	3.6 ± 0.5	0.2–0.8	0.001
Time to independent ambulation (days)	4.2 ± 0.5	0.3–0.8	3.6 ± 0.4	0.3–0.8	0.000
Postoperative discharge day	8.8 ± 1.1	0.5–1.5	7.7 ± 0.4	0.5–1.5	0.000

Student's *t* test was used for the analysis, and  $p < 0.05$  was considered statistically significant

SD, standard deviation; FAST group, preoperative fasting group; CHO group, preoperative carbohydrate loading group



epidural anaesthesia, which possibly modulated the magnitude of surgical stress and could influence the intervention [30].

In our study, the CHO drink did not significantly improve the VAS pain score. A prolonged time to the first analgesic dose in the CHO group might have been caused by the improvement in general well-being.

In the present study, the CHO drink reinforced the surgical outcomes. The postoperative return of gastrointestinal function was faster, and independent ambulation and the postoperative discharge day occurred one day earlier than in the FAST group. CHO treatment reduces protein loss, improves muscle function and promotes an anabolic state that may help in recovery after surgery [31]. A CHO drink helps avoid perioperative hyperglycaemia and alleviates PIR, which are two independent factors of the length of hospital stay [32]. Additionally, reduced anxiety and weakness scores and an earlier oral intake in the CHO group might be reasons for the earlier independent ambulation and discharge day. A meta-analysis of 21 clinical trials revealed a reduction in the length of hospital stay and PIR with preoperative CHO treatment in major abdominal surgery [33].

A preoperative CHO drink has a gastric passage time of less than 2 h and does not prolong the gastric emptying time [34]. In this study, there were no cases of taste intolerance, aspiration of gastric contents or adverse events connected with the oral fluid intake.

This study has some limitations. The evaluated parameters were monitored up to the second postoperative day. A longer follow-up would determine how long it takes to restore the metabolic and inflammatory parameters to basal values and whether the CHO drink accelerates this return. The obtained results refer only to participants with ASA physical status grades I and II. The inclusion of participants with ASA grade III or IV might be required to optimise the perioperative care and anaesthesia technique. Further research studies are needed to clarify some unresolved issues, e.g., the use of a CHO drink in patients with a higher ASA grade, diabetes mellitus or obesity.

In conclusion, a CHO supplement is a safe and effective practise in shortening preoperative fasting in open colorectal surgery. A CHO solution used the evening before surgery and 2 h before the induction of anaesthesia reduces PIR, attenuates the inflammatory response and improves subjective patient well-being. Additionally, a CHO drink allows for the faster return of gastrointestinal function, earlier independent ambulation and earlier postoperative discharge day. CHO loading did not significantly diminish postoperative pain. The use of preoperative CHO drinks should be a standard and widespread preoperative care practise, included in institutional protocols and accepted by surgical, anaesthesiologic and nursing teams in elective colorectal surgery.

**Author contributions** Rizvanović Nermina contributed to the conception and design of the study, the acquisition, analysis and interpretation of the data, and writing the original draft of the manuscript.

Nesek Adam Višnja contributed to the conception and design of the study, interpretation of the data, and review and editing of the manuscript.

Čaušević Senada contributed to conducting research and acquisition of the data.

Dervišević Senad contributed to conducting research and acquisition of the data.

Delibegović Samir contributed to the critical revision of the manuscript.

All authors read and approved the final manuscript. This manuscript is not being considered by any other journal.

## Compliance with ethical standards

**Conflict of interest** The authors declare that they have no competing interests.

**Statement of human rights** All procedures performed in this prospective randomised clinical trial (ClinicalTrials.gov registration ID: NCT03793036) involving human participants were conducted in accordance with the Declaration of Helsinki and its later amendments or comparable ethical standards. Ethical approval was obtained from the institutional ethical committee of Cantonal Hospital Zenica, Faculty of Medicine, University of Zenica (No. 20/1-2-4625/1).

**Informed consent** Written informed consent was obtained from each participant.

**Statement on the welfare of animals** This article does not contain any studies with animals performed by any of the authors.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

## References

1. Scott MJ, Baldini G, Fearon KC, Feldheiser A, Feldman LS, Gan TJ, Ljungqvist O, Lobo DN, Rockall TA, Schricker T, Carli F (2015) Enhanced recovery after surgery (ERAS) for gastrointestinal surgery, part 1: pathophysiological considerations. *Acta Anaesthesiol Scand* 59:1212–1231. <https://doi.org/10.1111/aas.12601>
2. Ljungqvist O, Jonathan E (2012) Rhoads lecture 2011: insulin resistance and enhanced recovery after surgery. *JPEN J Parenter Enteral Nutr* 36:389–398. <https://doi.org/10.1177/0148607112445580>
3. Akbarzadeh M, Eftekhari MH, Shafa M, Alipour S, Hassanzadeh J (2016) Effects of a new metabolic conditioning supplement on perioperative metabolic stress and clinical outcomes: a randomized, placebo-controlled trial. *Iran Red Crescent Med J* 18:e26207. <https://doi.org/10.5812/ircmj.26207>
4. Jodlowski T, Dobosz M (2014) Preoperative fasting - is it really necessary? *Pol Przegl Chir* 86:100–105. <https://doi.org/10.2478/pjs-2014-0019>

5. Nygren J (2006) The metabolic effects of fasting and surgery. *Best Pract Res Clin Anaesthesiol* 20:429–438. <https://doi.org/10.1016/j.bpa.2006.02.004>
6. Kratzung C (2011) Pre-operative nutrition and carbohydrate loading. *Proc Nutr Soc* 70:311–315. <https://doi.org/10.1017/S0029665111000450>
7. Sada F, Krasniqi A, Hamza A, Gecaj-Gashi A, Bicaj B, Kavaja F (2014) A randomized trial of preoperative oral carbohydrates in abdominal surgery. *BMC Anesthesiol* 14:93. <https://doi.org/10.1186/1471-2253-14-93>
8. Gianotti L, Biffi R, Sandini M, Marrelli D, Vignali A, Caccialanza R, Viganò J, Sabbatini A, Di Mare G, Alessiani M, Antomarchi F, Valsecchi MG, Bernasconi DP (2018) Preoperative oral carbohydrate load versus placebo in major elective abdominal surgery (PROCY): a randomized, placebo-controlled, multicenter, phase III trial. *Ann Surg* 267:623–630. <https://doi.org/10.1097/SLA.0000000000002325>
9. Witasp A, Nordfors L, Schalling M, Nygren J, Ljungqvist O, Thorell A (2010) Expression of inflammatory and insulin signaling genes in adipose tissue in response to elective surgery. *J Clin Endocrinol Metab* 95:3460–3469. <https://doi.org/10.1210/jc.2009-2588>
10. Perrone F, da-Silva-Filho AC, Adorno IF, Anabuki NT, Leal FS, Colombo T, da Silva BD, Dock-Nascimento DB, Damiao A, de Aguilar-Nascimento JE (2011) Effects of preoperative feeding with a whey protein plus carbohydrate drink on the acute phase response and insulin resistance: a randomized trial. *Nutr J* 10:66–72. <https://doi.org/10.1186/1475-2891-10-66>
11. Costa MD, Vieira de Melo CY, Amorim AC, Cipriano Torres Dde O, Dos Santos AC (2016) Association between nutritional status, inflammatory condition, and prognostic indexes with postoperative complications and clinical outcome of patients with gastrointestinal neoplasia. *Nutr Cancer* 68:1108–1114. <https://doi.org/10.1080/01635581.2016.1206578>
12. Gomez de Lima KV, Maio R (2012) Nutritional status, systemic inflammation and prognosis of patients with gastrointestinal cancer. *Nutr Hosp* 27:707–714. <https://doi.org/10.3305/nh/2012.27.3.5567>
13. Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Shibuya N, Kubota K (2016) Clinical significance of the C-reactive protein to albumin ratio for survival after surgery for colorectal Cancer. *Ann Surg Oncol* 23:900–907. <https://doi.org/10.1245/s10434-015-4948-7>
14. Kondrup J, Rasmussen HH, Hamberg O, Stanga Z, Ad Hoc ESPEN Working Group (2003) Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. *Clin Nutr* 22:231–236. [https://doi.org/10.1016/S0261-5614\(02\)00214-5](https://doi.org/10.1016/S0261-5614(02)00214-5)
15. Sio CA, Jung K, Kang SB, Kim DW, Oh HK, Yoon M (2015) The evaluation of preoperative oral carbohydrate-rich solution effects on insulin resistance in patients undergoing colectomy. *J Clin Nutr* 7: 62–67. <https://doi.org/10.15747/jcn.2015.7.2.62>
16. Kang ZQ, Huo JL, Zhai XJ (2018) Effects of perioperative tight glycemic control on postoperative outcomes: a meta-analysis. *Endocr Connect* 7:316–327. <https://doi.org/10.1530/EC-18-0231>
17. Gustafsson UO, Scott MJ, Schwenk W, Demartines N, Roulin D, Francis N, McNaught CE, Macfie J, Liberman AS, Soop M, Hill A, Kennedy RH, Lobo DN, Fearon K, Ljungqvist O, Enhanced Recovery After Surgery (ERAS) Society for Perioperative Care; European Society for Clinical Nutrition and Metabolism (ESPEN); International Association for Surgical Metabolism and Nutrition (IASMEN) (2013) Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS) Society recommendations. *World J Surg* 37:259–284. <https://doi.org/10.1007/s00286-018-4844-y>
18. Pinto AS, Grigoletti SS, Marcadenti A (2015) Fasting abbreviation among patients submitted to oncologic surgery: systematic review. *Arq Bras Cir Dig* 28:70–73. <https://doi.org/10.1590/S0102-67202015000100018>
19. Peixe-Machado PA, de Oliveira BD, Dock-Nascimento DB, de Aguilar-Nascimento JE (2013) Shrinking preoperative fast time with maltodextrin and protein hydrolysate in gastrointestinal resections due to cancer. *Nutrition* 29:1054–1059. <https://doi.org/10.1016/j.nut.2013.02.003>
20. Amer MA, Smith MD, Herbison GP, Plank LD, McCall JL (2017) Network meta-analysis of the effect of preoperative carbohydrate loading on recovery after elective surgery. *Br J Surg* 104:187–197. <https://doi.org/10.1002/bjs.10408>
21. Viganò J, Cereda E, Caccialanza R, Carini R, Cameletti B, Spampinato M, Dionigi P (2012) Effects of preoperative oral carbohydrate supplementation on postoperative metabolic stress response of patients undergoing elective abdominal surgery. *World J Surg* 36:1738–1743. <https://doi.org/10.1007/s00268-012-1590-4>
22. Tamura T, Yatabe T, Kitagawa H, Yamashita K, Hanazaki K, Yokoyama M (2013) Oral carbohydrate loading with 18% carbohydrate beverage alleviates insulin resistance. *Asia Pac J Clin Nutr* 22:48–53. <https://doi.org/10.6133/apjcn.2013.22.1.20>
23. Duggan EW, Carlson K, Umpierrez GE (2017) Perioperative hyperglycemia management: an update. *Anesthesiology* 126:547–560. <https://doi.org/10.1097/ALN.0000000000001515>
24. Dock-Nascimento DB, de Aguilar-Nascimento JE, Magalhães Faria MS, Caporossi C, Shlessarenko N, Waitzberg DL (2012) Evaluation of the effects of a preoperative 2-hour fast with maltodextrin and glutamine on insulin resistance, acute phase response, nitrogen balance, and serum glutathione after laparoscopic cholecystectomy: a controlled randomized trial. *JPEN J Parenter Enteral Nutr* 36:43–52. <https://doi.org/10.1177/0148607111422719>
25. Zelic M, Stimac D, Mendrila D, Tokmadzic VS, Fistic E, Urvacic M, Sustic A (2012) Influence of preoperative oral feeding on stress response after resection for colon cancer. *Hepatogastroenterology* 59:1385–1389. <https://doi.org/10.5754/hge10556>
26. Gomez de Lima KV, Maio R (2012) Nutritional status, systemic inflammation and prognosis of patients with gastrointestinal cancer. *Nutr Hosp* 27:707–714. <https://doi.org/10.3305/nh/2012.27.3.5567>
27. Sartelli M, Catena F, Abu-Zidan FM, Ansaloni L, Biffi WL, Boermeester MA, Ceresoli M, Chiara O, Coccolini F, de Waele JJ, di Saverio S, Eckmann C, Fraga GP, Giannella M, Girardis M, Griffiths EA, Kashuk J, Kirkpatrick AW, Khokha V, Kluger Y, Labricciosa FM, Leppaniemi A, Maier RV, May AK, Malangoni M, Martin-Loeches I, Mazuski J, Montravers P, Peitzman A, Pereira BM, Reis T, Sakakushev B, Sganga G, Soreide K, Sugrue M, Ulrich J, Vincent JL, Viale P, Moore EE (2017) Management of intra-abdominal infections: recommendations by the WSES 2016 consensus conference. *World J Emerg Surg* 12:22. <https://doi.org/10.1186/s13017-017-0132-7>
28. Weimann A, Braga M, Carli F, Higashiguchi T, Hübner M, Klek S, Laviano A, Ljungqvist O, Lobo DN, Martindale R, Waitzberg DL, Bishoff SC, Singer P (2017) ESPEN guideline. *Clin Nutr* 36:623–650. <https://doi.org/10.1016/j.clnu.2017.02.013>
29. Hausel J, Nyrgen J, Lagerkranser M, Hellstrom PM, Hammarqvist F, Almstrom C, Lindh A, Thorell A, Ljungqvist O (2001) A carbohydrate-rich drink reduces preoperative discomfort in elective surgery patients. *Anesth Analg* 93:1344–1350. <https://doi.org/10.1097/0000539-200111000-00063>
30. Henriksen MG, Hessov I, Dela F, Vind Hansen H, Haraldsted V, Rodt SA (2003) Effects of preoperative oral carbohydrates and peptides on postoperative endocrine response, mobilization, nutrition and muscle function in abdominal surgery. *Acta Anaesthesiol*

- Scand 47:191–199. <https://doi.org/10.1034/j.1399-6576.2003.00047.x>
31. Burgess LC, Phillips SM, Wainwright TW (2018) What is the role of nutritional supplements in support of total hip replacement and total knee replacement surgery: a systematic review. *Nutrients* 10: 820. <https://doi.org/10.3390/nu10070820>
  32. Fawcett WJ, Ljungqvist O (2017) Starvation, *carbohydrate loading, and outcome after major surgery*. *BJA Educ* 17:312–316. <https://doi.org/10.1093/bjaed/mkx015>
  33. Awad S, Varadhan KK, Ljungqvist O, Lobo DN (2013) A meta-analysis of randomised controlled trials on preoperative oral carbohydrate treatment in elective surgery. *Clin Nutr* 32:34–44. <https://doi.org/10.1016/j.clnu.2012.10.011>
  34. Sarin A, Chen L, Wick EC (2017) Enhanced recovery after surgery - preoperative fasting and glucose loading - a review. *J Surg Oncol* 116:578–582. <https://doi.org/10.1002/jso.24810>

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.